Abstract: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Abstract: Alternate methods for preparing functionalized pyridyl-amine products from pyridinyl starting materials are provided herein. In addition, these alternately-prepared functionalized pyridyl-amines can be used as ligands or ligand precursors in catalytic compositions, e.g. for use in alkene oligomerization reactions.

Abstract: The present invention provides crystalline forms of domain III of the West Nile Virus (“WNV”) envelope protein in complex with a Fab fragment of a neutralizing antibody, methods of obtaining such crystals and high-resolution structures and atomic structure coordinates. The crystals of the invention and the atomic structural information are useful for solving crystal and solution structures of related and unrelated proteins, and for screening for, identifying or designing compounds or antibodies that bind to, modulate a biological activity of, or neutralize infection mediated by flaviviral envelope proteins.

Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a chromium based catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl thioether compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.

Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl ether compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.

Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl phosphino compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.

Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a chromium based catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl mono-oxazoline compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.

Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a chromium based catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl bis(oxazoline) or pyridyl bis(thiazoline) ligand. In particular embodiments, the catalyst composition can be used to dimerize ethylene to butenes.

Abstract: A die micro electro-mechanical switch management system and method facilitate power conservation by selectively preventing electrical current from flowing in designated components. A present invention semiconductor die comprises a block of transistors for performing switching operations, a bus (e.g., a power bus, a signal bus, etc.) for conveying electrical current and a micro electro-mechanical switch that couples and decouples the block of transistors to and from the bus. The micro electro-mechanical switch is opened and closed depending upon operations (e.g., switching operations) being performed by the block of transistors. Electrical current is prevented from flowing to the block of transistors when the micro electro-mechanical switch is open and the block of transistors is electrically isolated. The micro electro-mechanical switch can interrupt electrical current flow in a plurality of the bus lines and/or can be included in a relay array.

Abstract: This invention relates to a method to selectively oligomerize olefins comprising contacting olefins with: 1) at least one diaryl-substituted diphosphine ligand; 2) a chromium metal precursor; and 3) optionally, one or more activators. In a particular embodiment, the method for selectively oligomerizing olefins includes trimerizing ethylene to selectively form 1-hexene.

Abstract: Aromatase inhibitors are administered to a female patient prior to endometrial ablation or resection procedures in order to thin the endometrium to a thickness of less than 6 mm, and preferably less than 4 mm, so as to enhance the treatment outcome. Of course, administration of aromatase inhibitors would be useful for other surgical procedures on the endometrial cavity and the uterus. Commercially available aromatase inhibitors, including, the nonsteroidal preparations, anastrozole and letrozole, and a steroidal agent, exemestane, are well-tolerated, and have been shown to decrease serum estrogen levels. The aromatase inhibitor can be used alone, or in combination with other aromatase inhibitors or pharmaceutical agents, such as hormones.

Abstract: Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In certain preferred embodiments, the aromatase inhibitor is administered in conjunction with methotrexate.

Abstract: One embodiment of a field changeable rendering system includes an output device interfaced to a motherboard, a fixed rendering device mounted to the motherboard for generating information to be output on said output device, a connector for attaching a field-changeable rendering card to the motherboard, said field-changeable rendering card capable of housing a discrete rendering device for generating information to be output on said output device and detection circuitry for detecting that a field-changeable rendering card housing a discrete rendering device is coupled to said connector and causing information from said field-changeable rendering card housing a discrete rendering device to be output on said output device. One advantage of the disclosed edge connector is that it is compatible with a plurality of graphics cards and systems, thereby enabling a computing device user to upgrade the existing device's graphics system.

Abstract: The present invention comprises a calculator for performing sewing calculations. The calculator includes a processor and an input device connected to the processor. A display is connected to the processor. Software operates on the processor to receive quilt function operands from the input device. The software calculates quilt function results and displays the quilt function results on the display. A method of performing calculations is also disclosed. The method includes receiving data related to quilt calculations. The results related to the quilt calculations are calculated and the results related to the quilt calculations are displayed.

Abstract: A graphics system and a multi-user computer system are disclosed. The graphics system comprises a graphics processing unit (GPU) for processing pixels. It further includes a multi-user manager for allocating pixel processing capability for each one of a plurality of users, wherein each user uses a display and an input device. Moreover, the graphics system has a plurality of user attributes for each user. The multi-user computer system comprises a central processing unit (CPU) and a disk drive configured to support a plurality of users. Further, the multi-user computer system includes the graphics system.

Abstract: A graphics processing unit, which includes a clock generator configured to generate a clock signal and a controller coupled to the clock generator. The controller is configured to receive the clock signal, compare the clock signal with a synchronization signal to generate a timing signal, and transmit the timing signal to a second graphics processing unit connected to the graphics processing unit.

Abstract: The present invention provides crystalline forms of domain III of the West Nile Virus (“WNV”) envelope protein in complex with a Fab fragment of a neutralizing antibody, methods of obtaining such crystals and high-resolution structures and atomic structure coordinates. The crystals of the invention and the atomic structural information are useful for solving crystal and solution structures of related and unrelated proteins, and for screening for, identifying or designing compounds or antibodies that bind to, modulate a biological activity of, or neutralize infection mediated by flaviviral envelope proteins.

Abstract: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Abstract: Methods for the prevention of adhesion formation and development, and for the stimulation of fibrosis, involve the administration of therapeutic formulations to a patient containing inhibitors or stimulators to selected molecular adhesion markers. The molecular markers of the invention include Caspase 2, Caspase 3, Caspase 9, PPAR?, PPAR?, PPAR?1, PPAR?2, and NF-kappa B.

Abstract: The present invention systems and methods facilitate configuration of functional components included in a remotely located integrated circuit die. In one exemplary implementation, a die functional component reconfiguration request process is engaged in wherein a system requests a reconfiguration code from a remote centralized resource. A reconfiguration code production process is executed in which a request for a reconfiguration code and a permission indicator are received, validity of permission indicator is analyzed, and a reconfiguration code is provided if the permission indicator is valid. A die functional component configuration process is performed on the die when an appropriate reconfiguration code is received by the die. The functional component configuration process includes directing alteration of a functional component configuration. Workflow is diverted from disabled functional components to enabled functional components.